FDA
-
-
-
-
-
-
-
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
-
-
-
-
-
-
-
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
-
-
-
-
-
-
-
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
-
-
-
-
-
-
-
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
-
-
-
-
-
-
-
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
-
-
-
-
-
-
-
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
-
-
-
-
-
-
-
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
-
322,253 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

